Anaconda Biomed, a spin-off from the Vall d’Hebron Research Institute (VHIR) and members of CataloniaBio & HealthTech, has completed the clinical trial it was conducting for Advanced Neurovascular Access (ANA), its next-generation catheter. The product could hit the market next year.

Anaconda says that the clinical results have been positive and that the steering committee in charge of evaluating the medical device decided to end the study with 74 patients enrolled, although initially it was expected to be 125, given the sufficient evidence which confirmed the safety and performance goals. This data has been published in Stroke.

ANA is a mechanical thrombectomy system that consists of a catheter that captures and aspirates thrombi that cause ischemic stroke. The device is inserted into the artery and allows the blood flow to be stopped, the blood clot to be captured, and leaves no traces remaining in the patient's circulation.

Founded in 2015 by Ofir Arad and Marc Ribó, the company has completed the clinical phase of the product and begins the regulatory phase in Europe (EMA) and the United States (FDA). Meanwhile, they have started to build a production plant in Sant Quirze del Vallès, with prospects of reaching the market next year.

Photo: complete figure here